• Phare
  • Validé par KD/KO

Anticorps Monoclonal anti-S100A4

S100A4 Monoclonal Antibody for WB, IHC, IF/ICC, ELISA

Hôte / Isotype

Mouse / IgG2a

Réactivité testée

Humain, souris

Applications

WB, IHC, IF/ICC, ELISA

Conjugaison

Non conjugué

CloneNo.

2G11B4

N° de cat : 66489-1-PBS

Synonymes

Fibroblast-specific protein-1, Fibroblast-specific protein 1, Fibroblast Specific Protein, CAPL, Calvasculin



Informations sur le produit

66489-1-PBS cible S100A4 dans les applications de WB, IHC, IF/ICC, ELISA et montre une réactivité avec des échantillons Humain, souris

Réactivité Humain, souris
Hôte / Isotype Mouse / IgG2a
Clonalité Monoclonal
Type Anticorps
Immunogène S100A4 Protéine recombinante Ag9019
Nom complet S100 calcium binding protein A4
Masse moléculaire calculée 101 aa, 12 kDa
Poids moléculaire observé 12 kDa
Numéro d’acquisition GenBankBC016300
Symbole du gène S100A4
Identification du gène (NCBI) 6275
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

S100A4 is a member of the S100 family of calcium-binding proteins. The S100 family members have been involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100A4 is known to localize to and function in the nucleus, cytoplasm of cells, and the extracellular space. S100A4 has also been shown to be associated with tumor growth, motility, invasion, metastasis, angiogenesis, apoptosis, and chemoresistance. It is a fibroblast-specific protein associated with mesenchymal cell morphology and motility, is expressed during epithelial-mesenchymal transformations (EMT) in vivo (PMID: 9362334). It is a specific prognostic marker for renal survival in patients with IgAN (PMID: 16105038). It is also an improved marker for lung fibroblasts that could be useful for investigating the pathogenesis of pulmonary fibrosis(PMID: 15618458). Overexpression of S100A4 is correlated with a worse prognosis inpatients with various types of cancer.

{{ptg:RelatedPrimaryAntibodies}}